Maven Securities’s Aldeyra Therapeutics ALDX Stock Holding History

Maven Securities’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100,000	Closed	-$1.14M	–	1043
2021 Q2	$1.14M	Buy	100,000 +97,333	+3,650%	+$1.17M	0.05%	390
2021 Q1	$32K	Buy	+2,667	New	+$30.7K	﹤0.01%	1117
2018 Q4	–	Sell	-72,464	Closed	-$989K	–	84
2018 Q3	$989K	Buy	+72,464	New	+$588K	0.36%	68

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Maven Securities's ALDX Position: Q3 2021 in Review

Maven Securities sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 100,000 shares — an estimated $1.14M sold.

Maven Securities first reported a position in ALDX in Q3 2018 and held it in 3 quarters. The position peaked at $1.14M in Q2 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

Maven Securities reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
Maven Securities sold 100,000 Aldeyra Therapeutics shares in Q3 2021, an estimated $1.14M.
Maven Securities first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 3 quarters.
Maven Securities's Aldeyra Therapeutics position peaked at $1.14M in Q2 2021.
117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.